76348-92-0

Basic information

• Product Name: ethyl 1-(4'-fluorophenyl)-3-(dimethylamino)prop-2-enone-2-carboxylate
• Synonyms: ethyl 1-(4'-fluorophenyl)-3-(dimethylamino)prop-2-enone-2-carboxylate
• CAS NO: 76348-92-0
• Molecular Weight: 265.284
• Mol File: 76348-92-0.mol
• Article Data: 6

Chemical Properties

• CAS DataBase Reference: ethyl 1-(4'-fluorophenyl)-3-(dimethylamino)prop-2-enone-2-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: ethyl 1-(4'-fluorophenyl)-3-(dimethylamino)prop-2-enone-2-carboxylate(76348-92-0)
• EPA Substance Registry System: ethyl 1-(4'-fluorophenyl)-3-(dimethylamino)prop-2-enone-2-carboxylate(76348-92-0)

Safety Data

• Hazardous Substances Data: 76348-92-0(Hazardous Substances Data)

Upstream product

• 403-42-9 1-(4-fluorophenyl)ethanone 
• 451-46-7 4-fluorobenzoic acid ethyl ester 
• 1999-00-4 ethyl 3-(4'-fluorophenyl)-3-oxopropionate 
• 4637-24-5 N,N-dimethyl-formamide dimethyl acetal 

Downstream Products

• 77995-13-2 4-(4-Fluoro-phenyl)-2-methyl-pyrimidine-5-carboxylic acid ethyl ester 
• 77995-10-9 2-Dimethylamino-4-(4-fluoro-phenyl)-pyrimidine-5-carboxylic acid ethyl ester 
• 77995-09-6 4-(4-Fluoro-phenyl)-pyrimidine-5-carboxylic acid ethyl ester 
• 77995-11-0 2-(Carbamoylmethyl-amino)-4-(4-fluoro-phenyl)-pyrimidine-5-carboxylic acid ethyl ester 
• 676233-16-2 5-(4-fluoro-phenyl)-1-(4-sulfamoyl-phenyl)-1H-pyrazole-4-carboxylic acid ethyl ester 
• 676233-07-1 5-(4-fluoro-phenyl)-1-(4-methanesulfonyl-phenyl)-1H-pyrazole-4-carboxylic acid ethyl ester 
• 797053-22-6 ethyl 5-(4-fluorophenyl)-1-phenyl-1H-pyrazole-4-carboxylate 
• 797053-28-2 1,5-bis-(4-fluoro-phenyl)-1H-pyrazole-4-carboxylic acid ethyl ester 
• 797053-29-3 1-(2,4-difluoro-phenyl)-5-(4-fluoro-phenyl)-1H-pyrazole-4-carboxylic acid ethyl ester 
• 797053-44-2 5-(4-fluoro-phenyl)-1-phenyl-1H-pyrazole-4-carbaldehyde 
• 797053-33-9 [5-(4-fluoro-phenyl)-1-phenyl-1H-pyrazol-4-yl]-methanol 
• 797053-50-0 1,5-bis-(4-fluoro-phenyl)-1H-pyrazole-4-carbaldehyde 
• 797053-39-5 [1,5-bis-(4-fluoro-phenyl)-1H-pyrazol-4-yl]-methanol 
• 797053-51-1 1-(2,4-difluoro-phenyl)-5-(4-fluoro-phenyl)-1H-pyrazole-4-carbaldehyde 

Relevant articles and documents

Molecular Oxygen-Mediated Minisci-Type Radical Alkylation of Heteroarenes with Boronic Acids

The carbon-carbon bond formation via autoxidation of organoboronic acid using 1 atm of O2 is achieved in a simple, clean, and green fashion. The approach allows a technically facile and environmentally benign access to structurally diverse heteroaromatics with medicinally privileged scaffolds. The strategy also displays its practicality and sustainability in the resynthesis of marketed drugs Crestor and pyrimethamine.

Lipid-Lowering Effects of Ethyl 2-Phenacyl-3-aryl-1H-pyrrole-4-carboxylates in Rodents

A series of substituted 2-phenacyl-3-phenyl-1H-pyrrole-4-carboxylates were prepared from substituted acetophenones in 6 steps. The final condensations between a chloroenal and an aminoketone were carried out under neutral conditions in parallel to yield the series listed below. Selected pyrrole derivatives proved to be potent hypolipidemic agents lowering serum triglyceride concentrations in CF-1 male mice after 14 days of I.P. administration. One agent orally lowered serum cholesterol in Sprague-Dawley male rats at 2 mg/kg/day after 14 days. The agents demonstrated a lowering of mouse serum LDL-cholesterol levels and selected compounds showed an elevation of serum HDL-cholesterol levels. The cholesterol concentrations in the liver were raised while the cholesterol and triglyceride contents of the aorta were significantly lowered by the selected trisubstituted pyrrole.

4-Substituted 1,5-diarylpyrazole, analogues of celecoxib: Synthesis and preliminary evaluation of biological properties

A number of 5-aryl-1-[4-(methylsulfonyl)-phenyl]-1H-pyrazoles and 4-(5-aryl-1H-pyrazol-1-yl)benzenesulfonamides 3, 4, 5, 6, analogues of the COX-2 selective inhibitor celecoxib (celebrex), were synthesized. In order to verify the effects on the biological properties of certain substituents put on position 4 of the pyrazole nucleus, some of these compounds were screened in vivo for their anti-inflammatory and analgesic activities. Moreover, sodium salts of carboxylic acids 4 were tested in vitro for their platelet anti-aggregating properties. The results of these preliminary biological assays showed that new derivatives are not endowed with improved anti-inflammatory and analgesic properties, in comparison with celecoxib. In addition, docking studies were carried out on the most significative compounds to evaluate their interaction mode at the active site of both COX-1 and COX-2. Some remarks about the SAR of this class of COX-inhibitors are drown out.